SCHEMBL1929499

SCHEMBL1929499

CCOC(=O)N1CC[C@@H](N2CCC(N3C(=O)C[C@H]4CCCC[C@@H]43)CC2)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.45
MAPK1 P28482 1/20 0.43
TP53 P04637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
ALOX12 P18054 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
THRB P10828 1/20 0.40
ATM Q13315 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8221542 1.00 CHRM1 (0.45) CHRM1MAPK1TP53TDP1SMN1; SMN2
SCHEMBL1928769 1.00 CHRM1 (0.45) CHRM1MAPK1TP53TDP1SMN1; SMN2
SCHEMBL1929062 0.93 CHRM1 (0.53) CHRM1MAPK1TP53TDP1SMN1; SMN2
SCHEMBL3405470 0.84 CHRM1 (0.44) CHRM1MAPK1TP53TDP1SMN1; SMN2
SCHEMBL5204555 0.83 L3MBTL3 (0.38) GAAL3MBTL1OPRM1OPRL1
SCHEMBL5201830 0.83 L3MBTL3 (0.38) GAAL3MBTL1OPRM1OPRL1
SCHEMBL8224025 0.83 L3MBTL3 (0.38) GAAL3MBTL1OPRM1OPRL1
SCHEMBL13697340 0.82 CHRM1 (0.44) CHRM1MAPK1TP53TDP1SMN1; SMN2
SCHEMBL1930009 0.80 OPRL1 (0.57) CHRM1MAPK1TP53TDP1CHRM2
SCHEMBL1929604 0.80 OPRL1 (0.57) CHRM1MAPK1TP53TDP1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US claimed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287695-A1 Novel Compounds OPRM1, OPRL1, OPRK1 CHRM1 6/4885MAPK1 2703/4885TP53 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.